Clinical trials: Calcific Uremic Arteriolopathy
Calciphylaxis, Calcific Uremic Arteriolopathy
Partners Calciphylaxis Biobank
Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles.
- Conditions
- Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease, Chronic Kidney Diseases
- Trial name
- PCB (NCT03032835)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Massachusetts General Hospital
Calciphylaxis, Calcific Uremic Arteriolopathy
Calciphylaxis in Patients With Chronic Kidney Disease - A Study of the Danish Calciphylaxis Research Initiative (DanCaRI)
Calciphylaxis is a rare yet life-threatening condition involving pronounced calcification in small blood vessels of the skin. Knowledge about its underlying mechanisms and contributing risk factors remains limited.
- Conditions
- Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease (ESRD), Chronic Kidney Diseases
- Trial name
- NCT07511283
- Where
- Denmark
- Volunteers
- 860 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Chronic Kidney Diseases, Calciphylaxis
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
- Conditions
- Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment
- Trial name
- NCT04592640
- Testing
- Human amniotic-derived mesenchymal stem cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Calciphylaxis, Calcific Uremic Arteriolopathy
Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy
To evaluate the efficacy of Sodium Thiosulfate (STS) compared to placebo, in reducing analgesic requirement in subjects with calcific uremic arteriolopathy (CUA) during an initial 28-day treatment phase.
- Trial name
- NCT02527213
- Testing
- Sodium thiosulfate
- Where
- 3 sites in United States
- Sponsor
- American Regent, Inc.
Calciphylaxis, Calcific Uremic Arteriolopathy
Phase 3 Study of SNF472 for Calciphylaxis
The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).
- Trial name
- Calciphyx (NCT04195906)
- Testing
- Experimental: SNF472, Experimatenl SNF472 (Open-label)
- Where
- 58 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Sanifit Therapeutics S. A.
Calciphylaxis, Calcific Uremic Arteriolopathy
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
Calcific uremic arteriolopathy a.k.a. calciphylaxis is a vascular calcification disorder seen in dialysis patients. Calcific uremic arteriolopathy has 60-80% one-year mortality and significant morbidity associated with…
- Trial name
- VitK-CUA (NCT02278692)
- Testing
- Vitamin K
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Calciphylaxis, Calcific Uremic Arteriolopathy
Phase 2 Study With SNF472 in Calciphylaxis Patients
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
- Trial name
- NCT02790073
- Testing
- SNF472
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 14 people
- Sponsor
- Sanifit Therapeutics S. A.
Calcific Uremic Arteriolopathy (CUA), Calciphylaxis
European Calciphylaxis Registry Network
Observational, registry, prospective, non-interventional collection of CUA patient data. Patient treatment is carried out within clinical routine, at the discretion of the physicians and according to existing treatment…
- Trial name
- EuCalNet (NCT02635373)
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- RWTH Aachen University